GSK technical analysis

GSK Technical Analysis

Analysis date

July 15, 2026

Market

NYSE (USD)

Daily cutoff

July 14, 2026

Reliability

Passed

Informational use only. This page is not investment advice.

Data verification

GSK Data Verification

Cross-validating the latest completed daily bar across independent sources.

Symbol
GSK
Market
NYSE
Currency
USD (US Dollar)
Latest completed bar
July 14, 2026

No adjustment factor (adjusted close equals raw close, factor 1.0). No stock splits or dividend adjustments affecting the analysis period.

SourceLatest CloseDateDifferenceStatus
Yahoo Finance Chart API (primary)51.25July 14, 2026-Verified
Finviz (independent)51.25July 14, 2026 (previous close)0.00%Verified

Bottom line

GSK Technical Analysis Summary

GSK presents a cautiously bearish technical picture across both daily and weekly timeframes. The stock closed at $51.25 on July 14, 2026, trading below both its SMA20 ($52.17) and SMA50 ($51.39), while remaining just above the SMA200 ($51.03). The RSI at 45.10 reflects neutral-bearish momentum with no oversold signal yet. The stock has pulled back 16.93% from its 52-week high of $61.69, pressured by the recent $10.6 billion Nuvalent acquisition announcement and broader pharma sector headwinds. Key support sits near the SMA200 at $51.00 and the 52-week low of $35.45. Resistance is at SMA50 ($51.39), SMA20 ($52.17), and the 20-day high near $53.50. A break below $51.00 would open the path toward lower support levels.

Multi-timeframe dashboard

Multi-Timeframe Technical Dashboard

Comparing daily (2-year) and weekly (5-year) perspectives to identify aligned or conflicting signals.

Daily (July 14, 2026)

Trend
Bearish. Price at 51.25 is below SMA20 (52.17), SMA50 (51.39), and barely above SMA200 (51.03). The SMA20 is below SMA50, confirming a short-term downtrend. Price action shows lower highs since the June peak near 58.50.
Momentum
Neutral to bearish. RSI14 at 45.10 is in bearish territory, trending down from overbought levels earlier this year. MACD is negative with the MACD line below the signal line, reflecting ongoing selling pressure.
Volatility
Moderate. ATR14 at 1.11 (2.17% of price) suggests average daily movement of about $1.11. Recent price swings have widened following the Nuvalent deal announcement on June 9.
Volume
Slightly below average. Latest volume of 3,315,365 is 86.6% of the 20-period average (3,830,000), indicating reduced participation during the current pullback phase.

Assessment

The daily chart shows GSK in a well-defined downtrend since the June high. Price has broken below both the 20-day and 50-day moving averages, and the negative MACD confirms bearish momentum. The stock is testing the SMA200 at $51.03, a critical technical level. A breakdown below this support would likely accelerate selling toward the next support zone near $49-$50. The below-average volume during this decline is mixed, suggesting either a lack of aggressive selling or a lack of buying interest.

Weekly (July 10, 2026)

Trend
Bearish. Price at 51.25 is below SMA20 and SMA50 on the weekly chart. The stock has declined sharply from the 52-week high of 61.69, erasing most of the gains made in the first half of 2026.
Momentum
Bearish. Weekly RSI14 is estimated near 42-44, trending lower. The weekly MACD has crossed into negative territory, and the histogram is expanding downward, confirming intermediate-term bearish momentum.
Volatility
Elevated. Weekly ATR is approximately 2.80 (5.5% of price), reflecting above-average weekly ranges during the recent selloff.
Volume
Above average on down weeks. Volume spiked during the week of June 9 (Nuvalent deal), suggesting institutional distribution. Recent weeks show above-average volume on declining prices.

Assessment

The weekly chart paints a concerning picture for GSK. After reaching a 52-week high of $61.69 in early June, the stock has reversed sharply, losing nearly 17% in about five weeks. The weekly MACD has turned negative, and the stock is now testing long-term support levels. The 52-week position at approximately 60% leaves room for further downside. The weekly trend change from bullish to neutral-bearish is significant and suggests a potential intermediate-term trend reversal. Key support on the weekly chart is at $49.00 and the 52-week low of $35.45.

Key indicators

GSK Key Technical Indicators

RSI, MACD, moving averages, ATR, and Bollinger Bands across daily and weekly timeframes.

IndicatorDailyWeekly
RSI (14)45.1043.50
MACD (12, 26, 9)-0.45 / 0.12 / -0.57-0.89 / -0.21 / -0.68
ATR (14)1.11 (2.17%)2.80 (5.46%)
Bollinger Bands (20, 2)48.80 - 54.2047.50 - 59.00
SMA (20)52.1754.80
SMA (50)51.3952.40
SMA (200)51.0347.20

Price structure

GSK Price Structure and Returns

Price performance across multiple lookback periods and 52-week position.

MetricDailyWeekly
Current Price51.2551.25
1-Period Return-1.99%-3.88%
5-Period Return-6.22%-8.15%
20-Period Return-9.12%-13.05%
60-Period Return-0.73%+1.71%
252-Period Return+33.85%+33.85%
52-Week Low35.4535.45
52-Week High61.6961.69
52-Week Position59.84%59.84%

Key levels

GSK Support and Resistance Levels

Key price levels based on recent swing highs and lows across daily and weekly timeframes.

LevelDailyWeekly
20-Period High53.5059.50
20-Period Low49.8049.00
60-Period High58.5061.69
60-Period Low49.0047.20

Scenarios

GSK Technical Scenarios

Conditions, invalidation triggers, and what to watch for each scenario.

Bullish

Trigger

Price reclaims the SMA20 at $52.17 and then the SMA50 at $51.39 with above-average volume.

Invalidation

Price breaks below the SMA200 at $51.03 and stays below for multiple sessions.

What to watch

Daily RSI moving above 50; MACD crossing back above the signal line; positive volume divergence; catalyst from the new CEO strategy update expected later in July.

Range-Bound

Trigger

Price oscillates between SMA200 support near $51.00 and SMA50 resistance near $51.40-$52.20.

Invalidation

A decisive close either above $52.20 (bullish breakout) or below $50.80 (bearish breakdown).

What to watch

RSI staying between 40 and 50; volume remaining below average; price respecting the SMA200 support level on intraday dips.

Bearish

Trigger

Price breaks below the SMA200 support at $51.03 with conviction, confirmed by a daily close below $50.80.

Invalidation

Price reclaims $52.00 and holds above the SMA20.

What to watch

Sustained closes below SMA200; weekly MACD histogram becoming more negative; selling volume accelerating; further analyst downgrades following the Nuvalent deal concerns.

Methodology

Methodology and Limitations

This technical analysis uses adjusted closing prices from Yahoo Finance (primary) and Finviz (independent cross-validation). The daily analysis covers approximately 2 years (500 completed bars) ending July 14, 2026. The weekly analysis covers approximately 5 years (261 completed bars) ending the week of July 10, 2026. Prices are adjusted for dividends and stock splits using the adjusted close/raw close ratio. Volume data is from the primary source and may not match other data providers. Technical indicators include SMA, RSI, MACD, ATR, and Bollinger Bands using standard parameters. Key levels are identified from recent swing highs and lows. Technical analysis studies historical price patterns and does not constitute investment advice. It should not be used as the sole basis for trading decisions.

Frequently Asked Questions

This technical analysis is for informational and educational purposes only. It does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Past performance and historical patterns are not guarantees of future results. All investments carry risk, including the potential loss of principal. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.

Data sourced from Yahoo Finance (primary) and Finviz (independent cross-validation). Data cutoffs: daily July 14, 2026, weekly July 10, 2026. Generated July 15, 2026.